SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Heart Failure

In "SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Heart Failure," Dr. Vaduganathan compares SGLT2 inhibitors with GLP-1 receptor agonists and where the evidence for each currently stands.

Dr. Vaduganathan compares SGLT2 inhibitors with GLP-1 receptor agonists, two classes he says have each revolutionized parts of cardio-kidney-metabolic care but that carry distinct, non-interchangeable indications. SGLT2 inhibitors, as covered earlier in the series, are recommended for at-risk type 2 diabetes, chronic kidney disease, and heart failure. GLP-1 receptor agonists, by contrast, have been well studied in type 2 diabetes and obesity, and evidence is beginning to emerge in obesity-related complications. He notes one large, well-controlled trial supporting GLP-1 use in type 2 diabetes-associated chronic kidney disease, giving that indication reasonably solid footing.

Heart failure is where Dr. Vaduganathan draws the sharpest distinction. The GLP-1 evidence base there is less robust, built on smaller to moderate trials that have suggested clinical benefit, particularly for health-related quality of life, but that have not yet demonstrated the kind of large-scale outcomes data SGLT2 inhibitors already have. He points out that roughly four large-scale trials are actively underway testing new GLP-1 compounds specifically in heart failure populations, powered to detect clinical outcomes rather than surrogate measures.

Until those trials read out, Dr. Vaduganathan says GLP-1 receptor agonists cannot be considered at the same level of scientific evidence as SGLT2 inhibitors for heart failure. He is direct about the practical implication: switching a patient off an SGLT2 inhibitor onto a GLP-1 receptor agonist does not represent an evidence-based therapeutic plan for that population, and he would not advise it. His guidance is to treat the two classes as complementary tools for different, specific indications rather than as substitutes for one another, at least until the heart failure evidence for GLP-1 receptor agonists matures.

In "Closing Screening Gaps for Cardio-Kidney-Metabolic Disease," the discussion turns to why so many at-risk patients still go undiagnosed for adjacent CKM conditions.